I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Ustyugova, Anastasia
42
results:
Search for persons
X
Format
Online (42)
Mediatypes
Articles (Online) (15)
OpenAccess-fulltext (27)
Sorted by: Relevance
Sorted by: Year
?
1
Cost-Effectiveness of Empagliflozin in Patients With Diabet..:
Reifsnider, Odette S.
;
Kansal, Anuraag R.
;
Wanner, Christoph
...
American Journal of Kidney Diseases. 79 (2022) 6 - p. 796-806 , 2022
Link:
https://doi.org/10.1053/..
?
2
Empagliflozin reduces cardiorenal events, healthcare resour..:
Nyström, Thomas
;
Toresson Grip, Emilie
;
Gunnarsson, Joel
...
Diabetes, Obesity and Metabolism. 25 (2022) 1 - p. 261-271 , 2022
Link:
https://doi.org/10.1111/..
?
3
Healthcare resource utilization in patients treated with em..:
Sheu, Wayne H‐H
;
Seino, Yutaka
;
Tan, Elise Chia‐Hui
...
Journal of Diabetes Investigation. 13 (2022) 5 - p. 810-821 , 2022
Link:
https://doi.org/10.1111/..
?
4
Healthcare Resource Utilization and Costs for Empagliflozin..:
Thomsen, Reimar W.
;
Christensen, Lotte W. B.
;
Kahlert, Johnny
...
Diabetes Therapy. 13 (2022) 11-12 - p. 1891-1906 , 2022
Link:
https://doi.org/10.1007/..
?
5
Cost-effectiveness of empagliflozin versus canagliflozin, d..:
Reifsnider, Odette S
;
Kansal, Anuraag R
;
Gandhi, Pranav K
...
BMJ Open Diabetes Research & Care. 9 (2021) 1 - p. e001313 , 2021
Link:
https://doi.org/10.1136/..
?
6
Cost-effectiveness of empagliflozin in patients with type 2..:
Ramos, Mafalda
;
Men, Peng
;
Wang, Xu
..
Cost Effectiveness and Resource Allocation. 19 (2021) 1 - p. , 2021
Link:
https://doi.org/10.1186/..
?
7
Cardiovascular Events, Acute Hospitalizations, and Mortalit..:
Thomsen, Reimar W.
;
Knudsen, Jakob S.
;
Kahlert, Johnny
...
Journal of the American Heart Association. 10 (2021) 11 - p. , 2021
Link:
https://doi.org/10.1161/..
?
8
Cost‐effectiveness of empagliflozin in the UK in an EMPA‐RE..:
Reifsnider, Odette S.
;
Kansal, Anuraag R.
;
Franke, Jennifer
...
ESC Heart Failure. 7 (2020) 6 - p. 3910-3918 , 2020
Link:
https://doi.org/10.1002/..
?
9
Effect of empagliflozin on exercise ability and symptoms in..:
Abraham, William T
;
Lindenfeld, JoAnn
;
Ponikowski, Piotr
...
European Heart Journal. 42 (2020) 6 - p. 700-710 , 2020
Link:
https://doi.org/10.1093/..
?
10
Long-Term Cost-Effectiveness Analyses of Empagliflozin Vers..:
Ramos, Mafalda
;
Cummings, Michael H.
;
Ustyugova, Anastasia
...
Diabetes Therapy. 11 (2020) 9 - p. 2041-2055 , 2020
Link:
https://doi.org/10.1007/..
?
11
Changes in SGLT2i and GLP-1RA real-world initiator profiles..:
Knudsen, Jakob S.
;
Baggesen, Lisbeth M.
;
Lajer, Maria
...
PLOS ONE. 15 (2020) 3 - p. e0229621 , 2020
Link:
https://doi.org/10.1371/..
?
12
Rationale and design of the EMPERIAL‐Preserved and EMPERIAL..:
Abraham, William T.
;
Ponikowski, Piotr
;
Brueckmann, Martina
...
European Journal of Heart Failure. 21 (2019) 7 - p. 932-942 , 2019
Link:
https://doi.org/10.1002/..
?
13
Cost-effectiveness Analysis of Empagliflozin in Japan Based..:
Kaku, Kohei
;
Haneda, Masakazu
;
Sakamaki, Hiroyuki
...
Clinical Therapeutics. 41 (2019) 10 - p. 2021-2040.e11 , 2019
Link:
https://doi.org/10.1016/..
?
14
Comparison of Oral Anticoagulants for Stroke Prevention in ..:
Tervonen, Tommi
;
Ustyugova, Anastasia
;
Sri Bhashyam, Sumitra
...
Value in Health. 20 (2017) 10 - p. 1394-1402 , 2017
Link:
https://doi.org/10.1016/..
?
15
Empagliflozin reduces cardiorenal events, healthcare resour..:
Nyström, Thomas
;
Toresson Grip, Emilie
;
Gunnarsson, Joel
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092061/. , 2022
Link:
http://www.ncbi.nlm.nih...
1-15